Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrants Reported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibody response for DYAI-100 a recombinant protein receptor binding domain (RBD) booster vaccine candidate for protection against COVID-19 infection Entered into several fully funded vaccine and antibody projects... Read More